The use of bacillus PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases

An intestinal disease, Bacillus technology, applied in the direction of using bacteria, medical raw materials derived from bacteria, medical preparations that are not active ingredients, etc.

Inactive Publication Date: 2009-06-03
KEMIN IND INC
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Potential emergence of vancomycin and metronidazole-resistant Clostridium difficile presents another risk factor for use of antibiotics for this disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The use of bacillus PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
  • The use of bacillus PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
  • The use of bacillus PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1: Efficacy of Bacillus PB6 against Clostridium difficile AAD and CDAD

[0037] The antagonism of Bacillus PB6 against Clostridium perfringens ATCC13124 and Clostridium difficile ATCC9689 was tested.

[0038] Bacillus PB6 has antagonistic effects on Clostridium perfringens ATCC 13124 and Clostridium difficile ATCC9689. A clear ring was observed at the intersection of the dashed lines on the plates of the two strains. An example of the assay plate is at figure 1 shown in .

[0039] Bacillus PB6 has antagonistic effect on Clostridium difficile N API / 027. This strain of C. difficile has been associated with several high-risk disease outbreaks and has shown resistance to antibiotics. An example of the assay plate is at figure 2 shown in .

[0040] To determine the antimicrobial effect of secondary metabolites of Bacillus sp. PB6, the bacteria were fermented and the fermentation products were extracted by diethyl ether. The organic layer was separated, concen...

Embodiment 2

[0152] Example 2: Determination of different probiotics and Bacillus amyloliquefaciens by broth microdilution Antimicrobial properties of PB6 metabolites against Clostridium perfringens and Clostridium difficile

[0153] In this study, we investigated the anti-clostridial properties of Bacillus sp. PB6 and metabolites of 4 commercially available probiotics: (Sanofi-synthelabo), (Biodiphar), Bioplus 2B (Miavit GmbH) and Biosporinum (Dniprofarm). Setting up small-scale fermentations using strains isolated from different probiotics. Ether extracts of fermentation broths containing the metabolites were screened against C. perfringens ATCC13124 and C. difficile ATCC9689 using broth microdilution. Metabolites of Bacillus PB6 showed significant anti-clostridial properties. The minimum inhibitory concentration is between 2.5 and 5.0 μg / ml (for C. perfringens) and between 5.0 and 10.0 μg / ml (for C. difficile). Ether extracts of Bioplus 2B and Biosporinum fermentation broths d...

Embodiment 3

[0168] Example 3: Efficacy of Bacillus PB6 against IBD

[0169] Surfactin is known to inhibit the activity of cytosolic PLA2, an enzyme primarily involved in many inflammatory processes 58 . Inhibition of inflammatory processes makes surfactin-producing probiotics of great interest for the treatment of inflammatory diseases such as inflammatory bowel disease (IBD).

[0170] Inflammatory bowel disease refers to two chronic diseases that cause intestinal inflammation: ulcerative colitis (UC) and Crohn's disease (CD). Although the diseases share some common features, they have some important differences.

[0171] CD is a chronic inflammation of the bowel wall that typically affects the entire thickness of the bowel wall. It most commonly occurs in the lowest part of the small intestine (ileum) and large intestine, but it can also occur in any part of the digestive tract from the mouth to the anus and the skin around the anus.

[0172] In the last decade, CD has become a mor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

Bacteria of the sp. Bacillus that produce a lipopeptide are found to be effective in the treatment and prophylaxis of gastro-intestinal disease when administered as a probiotic. In particular, a strain of Bacillus bacteria identified as PB6 is useful for the treatment of Antibiotic Associated Diarrhea (AAD) or the more serious condition Clostridium difficile associated diarrhea (CDAD) when administered as a probiotic. Additionally, these bacteria have been found efficient for the treatment of immunorelated diseases such as Inflammatory Bowel Disease (IBD).

Description

[0001] This application claims priority to US Patent Application Serial No. 60 / 740,518 filed November 29,2005. Background of the invention [0002] The present invention relates generally to the administration of bacteria to treat gastrointestinal disorders, and more particularly to the administration of Bacillus amyloliquefaciens strains to treat antibiotic-associated diarrhea (AAD) and Clostridium difficile-associated disease (CDAD). [0003] The term "antibiotic-associated diarrhea" refers to benign, self-limited diarrhea following the administration of antimicrobial agents. Typically, no causative agent has been identified for such diarrhea, which results from altered composition and function of the gut microbiota. Most patients responded to supportive measures and discontinuation of antibiotics. [0004] Long-term use of multiple antibiotics, especially broad-spectrum antibiotics with poor intestinal absorption or high bile secretion, leads to changes in the composition ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N63/00A61K35/742A61K38/16
CPCA61K35/742C12R1/07C12R1/125A23L1/3014A61K47/26A61K38/164A23L33/135A61P1/00A61P1/04A61P1/12A61P43/00C12R2001/125C12N1/205C12R2001/07A61K35/74
Inventor B·萨斯J·范赫梅尔J·范登凯尔克霍弗E·派斯H·M·谭C-Y·塞C·拉姆钱德J·瓦格海斯
Owner KEMIN IND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap